Caxton Associates LP Has $13.79 Million Stock Holdings in CME Group Inc. (NASDAQ:CME)

Caxton Associates LP increased its position in shares of CME Group Inc. (NASDAQ:CME) by 16.9% in the second quarter, HoldingsChannel reports. The firm owned 70,156 shares of the financial services provider’s stock after purchasing an additional 10,156 shares during the period. Caxton Associates LP’s holdings in CME Group were worth $13,793,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Gold Investment Management Ltd. bought a new stake in shares of CME Group during the fourth quarter worth $26,000. Salomon & Ludwin LLC bought a new stake in shares of CME Group during the first quarter valued at approximately $28,000. Y.D. More Investments Ltd bought a new position in CME Group in the 2nd quarter worth approximately $36,000. McClarren Financial Advisors Inc. lifted its holdings in CME Group by 66.1% during the 2nd quarter. McClarren Financial Advisors Inc. now owns 196 shares of the financial services provider’s stock worth $39,000 after buying an additional 78 shares in the last quarter. Finally, Asset Dedication LLC increased its stake in shares of CME Group by 515.2% in the 2nd quarter. Asset Dedication LLC now owns 203 shares of the financial services provider’s stock valued at $40,000 after buying an additional 170 shares during the period. 87.75% of the stock is owned by institutional investors.

CME Group Stock Up 1.1 %

NASDAQ:CME opened at $218.16 on Wednesday. The firm has a market capitalization of $78.55 billion, a price-to-earnings ratio of 24.82, a price-to-earnings-growth ratio of 8.74 and a beta of 0.55. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.10. CME Group Inc. has a twelve month low of $190.70 and a twelve month high of $223.80. The stock’s 50 day moving average price is $208.65 and its two-hundred day moving average price is $207.41.

CME Group (NASDAQ:CME) last issued its earnings results on Wednesday, July 24th. The financial services provider reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.03. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.53 billion. CME Group had a net margin of 56.98% and a return on equity of 12.82%. CME Group’s quarterly revenue was up 12.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.30 EPS. Equities research analysts expect that CME Group Inc. will post 9.94 earnings per share for the current fiscal year.

CME Group Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 25th. Shareholders of record on Monday, September 9th will be issued a $1.15 dividend. The ex-dividend date is Monday, September 9th. This represents a $4.60 annualized dividend and a dividend yield of 2.11%. CME Group’s dividend payout ratio is currently 52.33%.

Insider Transactions at CME Group

In other news, CFO Lynne Fitzpatrick sold 754 shares of the stock in a transaction that occurred on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total transaction of $163,610.46. Following the transaction, the chief financial officer now owns 13,261 shares in the company, valued at $2,877,504.39. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other CME Group news, CFO Lynne Fitzpatrick sold 754 shares of the stock in a transaction that occurred on Sunday, September 15th. The shares were sold at an average price of $216.99, for a total transaction of $163,610.46. Following the transaction, the chief financial officer now owns 13,261 shares in the company, valued at approximately $2,877,504.39. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bryan T. Durkin sold 7,593 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $214.59, for a total value of $1,629,381.87. Following the completion of the sale, the director now owns 55,607 shares of the company’s stock, valued at $11,932,706.13. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have weighed in on CME. Bank of America cut CME Group from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $212.00 to $177.00 in a report on Tuesday, September 3rd. Deutsche Bank Aktiengesellschaft increased their price target on CME Group from $193.00 to $200.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Keefe, Bruyette & Woods boosted their target price on CME Group from $212.00 to $213.00 and gave the stock a “market perform” rating in a research report on Thursday, July 25th. Piper Sandler reissued an “overweight” rating and set a $225.00 price objective on shares of CME Group in a research note on Tuesday, August 20th. Finally, JPMorgan Chase & Co. lifted their price target on shares of CME Group from $187.00 to $191.00 and gave the stock an “underweight” rating in a research report on Thursday, July 25th. Four research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $209.73.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.